Overview

Lymphoma is a type of cancer that deals with the blood, characterised by the customized production of a certain type of WBC called lymphocytes. They are placed in your body’s immune system by categorising them into lymphocytes. They wander in your body via your lymphatic system and bloodstream in order to assist you in fighting off infections.

There are two types of lymphocytes: T helper cells, helper T cells, and B cells. This is important to note because there is, in fact, an extremely extensive range of varieties of this illness known as lymphoma. Mantle cell lymphoma can be one of the subcategories of non-Hodgkin lymphoma cancer that is B-cell derived. It is called a 'mantle cell' because the neoplastic B lymphocytes are derived from the 'mantle' area of the lymph node.¹ 

Mantle cell lymphoma can also be called B-cell non-Hodgkin’s lymphoma, and is among the related cancers that influence the lymphatic system. As described earlier, since the lymphatic system is a subsystem of the immune system, it assists the immune system in managing diseases and disease-causing organisms. It is comprised of a sequence of tubes of lymph known as lymph vessels, which transcribe a faint yellowish fluid referred to as the lymph from the different structures of the body back to blood circulation. Lymph is present in intercellular space and constituencies of it include water, proteins, fats, and a type of white blood cell referred to as lymphocyte.

As lymph moves through the lymphatic system, it is filtered by a network of small structures known as lymph nodes, which are always involved in the filtration of microorganisms like viruses, bacteria, and others, as well as other foreign bodies. Lymph nodes are present in groups; they are present in some areas of the neck, under the arms (axillary), near the elbows and chest, abdomen, and groins. Lymphocytes are saved in the lymph nodes and can also be found in other organ structures of the lymphoid system. Lymphatic tissues include the spleen is also a part of this body system, the lymphatic system. Lymphatic tissues are divided into the thymus, a small organ situated just behind the sternum, and the bone marrow, which is a spongy tissue found in the bone marrow cavities and has the function of blood cell formation. In some way, a similar can be mentioned about the other parts of the body, like skin, small intestine, liver, and some other organs. Here, it is necessary to describe lymphatic tissue and or circulating lymphocytes. There are two main types of lymphocytes: B-lymphocytes, which may release specific antibodies that “neutralise” some of the invading microbes, and T-lymphocytes, which may either directly ‘kill’ the microbes or assist other sub-types of lymphocytes. 

Mantle cell lymphoma and other kinds of lymphomas are generated either by the mutation of a lymphocyte or by the transformation of a normal lymphocyte into a neoplastic one. These malignant lymphocytes may proliferate abnormally and cause numerous issues, such as the enlargement of a specific segment of the affected lymph node. It may also involve other related tissues and organs, namely the spleen and bone marrow, and metastases to other tissues of the body, which could prove fatal.²

Risk factor

There are certain conditions or factors that can increase an individual’s tendency to get lymphoma:³

• If the immune system has been weakened by medicines, some illnesses may be more probable. Other persons who are considered immunocompromised include those who are on drugs that dull the immune system, such as a person who has undergone a transplanted organ. HIV also leads to low immunity, in addition to several other illnesses or disorders
• It is also important to note that close relations with first-degree family members diagnosed with lymphoma are also certain to develop the disease one day
• Depending on the type of infection, a person may be at high risk for lymphoma. Epstein-Barr virus, Helicobacter pylori, and HIV are among them. Certainly, there are certain forms of lymphoma which are characterised by their propensity to affect teenagers and young adults
• Some develop in individuals in a certain age group; for instance, they are more recurrent in seniors who are persons of more than 55 years of age

Causes

MCL patients present with a consistent genetic abnormality that occurs as an interchange between chromosomes 11 and 14. This type is referred to as ‘reciprocal translocation’ and is simply denoted by t(11;14). The t(11;14) translocation develops when portions of chromosome 11 and chromosome 14 flip over. It happens at the chromosomal region 11, containing the cyclin D1 gene as well as at the chromosomal region 14 which contains the gene that controls the formation of antibody molecules.

This leads to the formation of cyclin D1, which encourages tumour cell division and growth in the body. Cyclin D1 is not normally produced in normal lymphocytes without any disease. Either the numeric or qualitative upregulation of cyclin D1 protein contributes to the large numbers of MCL cell mass. The majority of the patients suffering from MCL have t, which leads to overexpression of the cyclin D1. A few, however, appear to present without cyclin D1 -negative but rather present an overexpression of the proteins cyclin D2 or D3.

Increased levels of the transcription factor SOX11 (transcription factors are proteins involved in the activation of gene expression, and they require binding to DNA). SOX11 is overexpressed in about 95% of patients with classical MCL, including cases either positive or negative for cyclin D somewhere in the vicinity of the chromosome. This may potentially aid in stratifying the angrily expressed cyclin D1-negative MCL from other B-cell neoplasm entities.⁴

Types

MCL is further divided into two subgroups:⁴

1. Classic MCL is the most frequent subtype of the disease, mostly characterised by lymph node or extra-nodal Lymphoma at diagnosis time and poor prognosis. Patients with the classic MCL have unmutated IGHV gene rearrangement, SOX11 overexpression, and genetic change (mutations) when compared with MCL patients with mutated IGHV* gene rearrangement
2. Leukemic non-nodal MCL is diagnosed in 10% to 20% of the patients diagnosed with MCL. From our results, it was clear that most patients presented with raised lymphocyte count and splenomegaly. Of this subset, nearly all express IGHV mutation, do not overexpress SOX11, and are relatively more genetically stable. Non-nodal leukemic MCL is seen in most of the presentations and is characterised by an indolent nature of the disease and a better prognosis

Clinical presentations

This type of cancer has many symptoms and will be illustrated throughout the passage. These are some of the general symptoms, which are diseases that affect an individual physically but are not easily assumed to be cancer symptoms. And that is why currently, most people are often diagnosed with mantle cell lymphoma, already having the disorder throughout the body.

Some signs are called B symptoms because they are direct pointers to B-cell lymphoma by healthcare providers. Signs of B are night sweats, high unexplained fever, fevers that one cannot manage using over-the-counter medicine, and a loss of weight. This is the usage of losing at least 10% of the weight within six months and without having to go on a diet or exercise. Other symptoms are:^3,5

• Intension in the stomach such as nausea and vomiting or diarrhoea
• Lumps in the region that includes your neck, armpits, or groin region that feels swollen or enlarged
• Stomach burning, discomfort in the abdomen, or gas
• Some feelings of fullness and discomfort due to the presence of big tonsils or hepatomegaly or splenomegaly
• Backache, which may be a dull or a sharp pain in the lower region of the back or stiffness, it may accompany pain in one or both legs
• Itchy skin
• Fatigue
• Anaemia (which causes feelings of tiredness) and shortness of breath
• Thrombocytopenia, which makes you more likely to bruise and bleed
• Neutropenia, which may increase your susceptibility to infection

Diagnosis

Proper staging and understanding of the disease entails the correct diagnosis of the patient’s exact subtype as mantle cell lymphoma. Every patient must be presented to a haematologist-oncologist, who is a doctor who treats or deals with blood cancer patients. The assessment process of newly diagnosed MCL must include:^4,5

• Physical examination, focusing specifically on lymph node regions
• Assessment of a patient's functional status, measuring their capability to independently carry out basic daily tasks (ADLs)
• Presence of lymphoma symptoms 

Laboratory tests should include: 

• Complete blood count (CBC) with differential
• Lactate dehydrogenase (LDH) test
• Comprehensive metabolic panel (CMP)
• Uric acid level test
• Bone marrow aspiration and biopsy
• Lymph node biopsy
• Computed tomography (CT) scan
• Positron emission tomography (PET) scan
• Esophagogastroduodenoscopy (EGD)
• Colonoscopy

Treatment

The decision to start treatment will depend on several factors, including:

• The patient’s age
• The patient’s fitness
• The presence of symptoms
• The patient’s MIPI risk category
• Ki-67 proliferative index
• Cell variant
• MCL group (nodal vs leukemic non-nodal)
• Other, still unknown, factors—genetic anomalies, for instance

Mantle cell lymphoma is generally considered an aggressive (fast-growing) type of NHL, and most MCL patients receive treatment following diagnosis and staging. However, for a small number of patients who have slow-growing (indolent) MCL and are otherwise healthy, doctors may recommend a period of close observation, called “watchful waiting” or “watch and wait.”

Treatment for Young, Fit Patients

For fit and generally younger patients, the treatment of choice involves:⁵

• Chemotherapy
• Monoclonal therapy
• Immunotherapy
• Radiation therapy
• CAR-T cell therapy
• Maintenance therapy
• Autologous stem cell transplantation

Summary

Overall, mantle cell lymphoma is a form of blood cancer in lymphocytes located within the lymph nodes and is sometimes caused by genetic abnormalities. Diagnosis involves a series of tests, and treatment options are available depending on age and health conditions. Common symptoms include night sweats, weight loss, fatigue, and generally unwell feelings, with the basis of treatment keeping the cancer under close monitoring, if not fully treated, to alleviate the quality of life.